ArticleCancer gene therapy2017
Identification of differentially expressed genes and their upstream regulators in colorectal cancer.
Article in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Machine learning-based meta-analysis of colorectal cancer and inflammatory bowel disease.PloS one · 2023Pooled it
- Molecular classification of colorectal cancer using the gene expression profile of tumor samples.Experimental biology and medicine (Maywood, N.J.) · 2019Trial
- Mechanisms of angiopoietin-like protein 7 regulation and therapeutic potential in tumors.Molecular biology reports · 2026Review
- An organotypic atlas of human vascular cells.Nature medicine · 2024Article
- Identification of Single Nucleotide Polymorphisms Through Genome-Wide Association Studies of pH Traits in Goose Meat.Biology · 2024Article
- Activation of CHPF by transcription factor NFIC promotes NLRP3 activation during the progression of colorectal cancer.Functional & integrative genomics · 2024Article
- Identification of candidate biomarkers and prognostic analysis of recurrence in colorectal cancer.Cancer biomarkers : section A of Disease markers · 2024Article
- Identification of potential prognostic markers for lung adenocarcinoma using comprehensive analysis.Molecular medicine reports · 2023Article
- Article
- Panomics reveals patient individuality as the major driver of colorectal cancer progression.Journal of translational medicine · 2023Article
- Alterations in Gene Pair Correlations as Potential Diagnostic Markers for Colon Cancer.International journal of molecular sciences · 2022Article
- A Novel Ferroptosis-Related Biomarker Signature to Predict Overall Survival of Esophageal Squamous Cell Carcinoma.Frontiers in molecular biosciences · 2021Article
- Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma.Pathology oncology research : POR · 2020Article
- PBMC gene expression profiles of female Bangladeshi adults chronically exposed to arsenic-contaminated drinking water.Environmental pollution (Barking, Essex : 1987) · 2020Article
- FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling.OncoTargets and therapy · 2020Article
- OMICfpp: a fuzzy approach for paired RNA-Seq counts.BMC genomics · 2019Article
- Article
- Identification of candidate genes and long non-coding RNAs associated with the effect of ATP5J in colorectal cancer.International journal of oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify the differentially expressed genes (DEGs) and their transcription factors (TFs) in colorectal cancer (CRC). We performed an integrated analysis of microarray studies. Functional annotation and CRC-specific transcriptional regulatory network construction were performed. Expression of selected DEGs and TFs was verified with The Cancer Genome Atlas (TCGA) data sets and qRT-PCR. SurvMicro was used to analyze the correlation between the overall survival time of CRC patients and the expression of DEGs and TFs. Seven data sets were obtained and 2014 DEGs in CRC were identified. Pathways in cancer and fatty acid metabolism were significantly enriched pathways of upregulated and downregulated DEGs, respectively. Expression of five DEGs (RERGL, ESM1, CA1, ANGPTL7 and TMEFF2) and their five TFs (ZNF354C, ARID3A, NFIC, BRCA1 and ZEB1) was verified by TCGA data sets and qRT-PCR. Their expression in TCGA data sets was same as that in our integrated analysis. Only the expression of EMS1, NFIC, BRCA1 and ZEB1 was inconsistent with integrated analysis and TCGA data sets. Expression of RERGL and BRCA1 was significantly correlated with the overall survival time of CRC patients. These five DEGs may have roles in CRC regulated by their five upstream TFs, which may make a contribution in uncovering the mechanism and providing new strategy of diagnosis and therapies for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.